5,534 Shares in IQVIA Holdings Inc. $IQV Acquired by Chicago Capital LLC

Chicago Capital LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,534 shares of the medical research company’s stock, valued at approximately $872,000.

Other large investors have also modified their holdings of the company. American National Bank & Trust purchased a new position in IQVIA in the first quarter valued at $26,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC raised its position in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA in the 1st quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. grew its position in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after buying an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 5.1%

NYSE:IQV opened at $189.96 on Wednesday. The company has a market capitalization of $32.29 billion, a PE ratio of 27.49, a P/E/G ratio of 1.98 and a beta of 1.32. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $237.34. The stock’s 50 day moving average price is $187.49 and its 200 day moving average price is $167.18. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IQV. Evercore ISI raised their target price on shares of IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a report on Wednesday, July 9th. Barclays raised their price objective on shares of IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, July 23rd. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Cowen restated a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Eighteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $229.64.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.